ELDN
Eledon Pharmaceuticals Inc

6,584
Mkt Cap
$199.73M
Volume
502,078.00
52W High
$4.60
52W Low
$1.35
PE Ratio
-2.21
ELDN Fundamentals
Price
$2.60
Prev Close
$2.66
Open
$2.56
50D MA
$2.00
Beta
0.86
Avg. Volume
707,226.31
EPS (Annual)
-$0.7454
P/B
4.50
Rev/Employee
$0.00
$60.78
Loading...
Loading...
News
all
press releases
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Average Recommendation of "Hold" by Brokerages
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) has been given an average rating of "Hold" by the five research firms that are currently covering the stock, MarketBeat Ratings reports...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for Tego at Conference
Eledon Pharmaceuticals (NASDAQ:ELDN) executives discussed recent clinical results and upcoming regulatory plans for its investigational immunosuppressive therapy, referred to in the discussion as...
MarketBeat·18d ago
News Placeholder
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Rating of "Hold" by Brokerages
Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the stock, MarketBeat reports. One...
MarketBeat·26d ago
News Placeholder
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Recommendation of "Hold" by Analysts
Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are covering the company, Marketbeat...
MarketBeat·2mo ago
News Placeholder
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
The End of Shots? 5 Biotech Stocks Rethinking Diabetes The End of Shots? 5 Biotech Stocks Rethinking Diabetes PR Newswire VANCOUVER, BC, Dec. 31, 2025 Issued on behalf of Avant Technologies Inc...
PR Newswire·2mo ago
News Placeholder
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Average Rating of "Hold" from Analysts
Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have been given a consensus rating of "Hold" by the five brokerages that are covering the stock, MarketBeat Ratings reports. One...
MarketBeat·3mo ago
News Placeholder
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) have been assigned a consensus rating of "Hold" from the five research firms that are currently covering the firm, MarketBeat...
MarketBeat·3mo ago
News Placeholder
Guggenheim Cuts Eledon Pharmaceuticals (NASDAQ:ELDN) Price Target to $8.00
Guggenheim decreased their price objective on shares of Eledon Pharmaceuticals from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday...
MarketBeat·3mo ago
News Placeholder
Eledon Pharmaceuticals (NASDAQ:ELDN) Releases Earnings Results, Beats Expectations By $0.01 EPS
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) announced its earnings results on Friday. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01...
MarketBeat·4mo ago
News Placeholder
Best Momentum Stocks to Buy for July 14th
ELDN, KDDIY and PENG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2025.
Zacks·8mo ago
<
1
2
...
>

Latest ELDN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.